For successful gene vaccination and therapy of cancer, it is essential to develop gene delivery vectors that can meet clinical and social requirements. The need for improved vectors was clearly manifested during the peak of the first wave of gene therapy. Adenoviral (Ad) vectors have recently drawn the attention of many of those involved in the field of gene therapy for cancer because of their practical advantages and application potential. Many experiments, innovations, preclinical studies, and clinical trials have generated an overwhelming amount of data and literature concerning this vector system. It is hoped that the comprehensive review presented here, which includes the principles, potential, capacity, and limitations of the current Ad systems, will help to further the rational development of the system. The literature in this article is organized in an attempt to emphasize Ad vector development in the aspects of technical approaches, practical hurdles and strategies to overcome them, significant experimental results, recent advances, future directions, etc. The technical range of this review covers details that are intended to serve as a reference for advanced technical readers and provide a foundation for initiates in the field of Ad vector gene therapy. The material presented here is also intended for nontechnical persons who want to have an overview of the significance and potential of the technology.
T here are several elements of concern with regard to the safety and efficacy for gene therapy of cancer: (a) the target tissue, (b) the transgene and its delivery and expression, and (c) host responses. Among these, gene delivery is a key element. The development of gene delivery methods or vectors has therefore become a major focal point of various efforts in the field of cancer gene therapy.
From studies performed during the first wave of gene therapy of cancer, genetic medicine is faced with a clear mandate for the additional development of suitable clinical vectors that are expected to lead the second wave. The requirements of an ideal gene delivery vector for cancer treatment should be evaluated based on the following criteria:
• high gene-transfer efficiency;
• large gene-carrying capacity;
• selective gene delivery;
• controlled cytotoxicity;
• regulated immunogenicity;
• ease of construction and manipulation;
• cost-effective production;
• safe and convenient application;
• acceptance by clinicians and patients.
However, a generally dominant gene delivery vector has not yet been developed. Several methodologies that have been invented thus far and that are undergoing initial proof-of-concept evaluation have the potential to be further developed to meet those requirements. Adenoviral (Ad) vectors are one of the potential candidates, for the following reasons:
• Ad vectors have been studied widely and are well characterized as a model system for eukaryotic gene regulation, which serves as a solid base for vector development.
• Ad vectors have a middle size of genome (average is 36 kilobases (kb)) that is suitable for the development of large-capacity vectors with minimal viral sequence.
• The vectors are easy to generate and manipulate.
• They are relatively stable and can be readily obtained in high titers (e.g., 10 11 -10 12 plaque-forming units (PFU)/mL).
• They exhibit a broad host range in vitro and in vivo, with high infectivity; this range is also seen in nondividing cells.
• Because the life cycle of the Ad does not require integration into the host cell genome, the foreign genes delivered by Ad vectors are expressed episomally, having low genotoxicity if applied in vivo.
• The vectors can be introduced to different tissues via a variety of routes of administration.
• No significant side effects have been reported following early clinical application or vaccination with wild-type (wt) live Ad, demonstrating the safety of this type of vector for in vivo gene transfer. The characteristics of Ad make this vector system amenable to be developed for gene therapy in two opposingapplications: (a) to genetically change the target cell without rejection by the host or (b) to evoke killing of malignant target cells. On one hand, the high capacity and efficiency of these vectors for gene delivery in vivo and their wide spectrum of infectivity can be applied for gene therapy of hereditary genetic diseases, which requires that the vector-treated cell survive and remain functional. On the other hand, their features of cytotoxicity, induction of inflammation, and immunogenicity for both humoral and cellular responses can be applied for the development of vectors for vaccines and gene therapy of cancer, which requires the selective killing of cancer cells along with the induction of host anticancer immunity (Fig 1) .
During the last several years, Ad vectors have drawn much attention from scientists and clinicians because the rapid development of different gene therapy approaches has led to increased gene delivery capacity, control of their immunogenicity, and renovation of their virological characteristics. The application value of Ad vectors as one of the potential in vivo gene delivery vehicles for gene therapy and the prevention for cancer has been demonstrated with a few recent, important breakthroughs using animal model systems. It is the intention of this article to review the history and methodology of Ad vector development, to discuss the limitation of this vector system, to analyze the strategies to overcome the hurdles, and to evaluate the feasibility and developmental potential of the vectors for clinical application in the treatment and prevention of cancer.
BASIC Ad VECTOR TECHNOLOGY

Basics of Ad virology
Ad consists of nonenveloped icosahedral (20 facets and 12 vertices) protein capsids with a diameter of 60 -90 nm and inner DNA/protein cores. 1 The outer capsid is composed of 252 capsomers arranged geometrically to form 240 hexons (12 hexons per facet) and 12 penton bases; the latter are located at each vertex, from which protrude the antenna-like fibers. This structure is responsible for the attachment of Ad to cells during infection. Wt Ad contains 87% protein and 13% DNA and has a density of 1.34 g/mL in CsCl.
Serotype and group
Serologically, Ads have been classified into ϳ47 distinct serotypes. 1 The different Ad serotypes have been subgrouped from A to F based on genome size, organization, homology, nucleotide composition, animal oncogenicity, etc. Among all of the serotypes, the most well studied in virology and molecular biology are the group C viruses, which consist of Ad serotypes 1, 2, 5, and 6. The serotypes 2 and 5 (Ad2 and Ad5) are most commonly used for gene delivery vector development.
Important cis elements
The double-stranded linear DNA genome of Ad is ϳ36 kb long and is conventionally divided into 100 map units Figure 1 . Ad vector as a double-edged sword. The virological and biological features of Ad make it applicable for the development of vectors intended for either of two diametrically opposed objectives in genetic medicine, depending upon whether target cells are to be killed or kept alive. On one hand, the cytotoxic and immunogenic nature of Ad can be used for gene therapy of cancer. On the other hand, the high infectivity as well as the potential for effective transgene delivery and sustained gene expression can be used for gene therapy of hereditary diseases. The strategy and approach toward the research and development of new Ad vectors can be very different, although basic virology and the related technology of Ad vectors are still useful for both types of applications.
(mu). Each end of the viral genome has a 100-to 150-base pair (bp) repeated DNA sequence known as the inverted terminal repeat (ITR). The left end (194 -385 bp) contains the signal for encapsidation (packaging signal). Both of the ITRs and the packaging signal are the cis-acting elements, which are necessary for viral DNA replication and packaging. 2, 3 Transcriptional units A simplified map of the Ad5 genome with a few key landmarks is diagrammed in Figure 2 . 4, 5 The early (E) and late (L) regions of the genome that contain different transcription units are divided according to the onset of viral DNA replication. The E1 region (E1A and E1B) encodes proteins responsible for the regulation of transcription of the viral genome as well as a few cellular genes. 6 Expression of the E2 region (E2A and E2B) leads to the synthesis of the proteins needed for viral DNA replication. 7 The proteins from the E3 region prevent cytolysis by cytotoxic T cells and tumor necrosis factor. 8 The E4 proteins are involved in DNA replication, late gene expression and splicing, and host cell shutoff. 9 The products of the late genes, including the majority of the viral capsid proteins, are expressed after processing a 20-kb primary transcript driven by the major late promoter (MLP). 10 The MLP (located at 16.8 mu) is particularly efficient during the late phase of infection, and all the mRNAs issued from this promoter possess a 5Ј tripartite leader sequence, which makes them preferred over the cellular mRNA for translation.
Infection and viral receptors
The infection spectrum of human Ad is wide with respect to different types of tissue and different age groups of patients. 11 Although Ad vectors have been demonstrated to deliver transgenes into diverse types of tissue and cultured cells with either cycling or noncycling status, the vectors do vary in their infectivities for different types of cells, including cell lines of the same lineage, which may be dependent upon the availability of the Ad receptors on the target cell surface. 12 Entry of human Ad into host cells involves interactions of virus particles with two separate cellular receptors. Initial binding of Ad to target cells is a fiber protein-mediated attachment to a cellular receptor, 13, 14 which was identified recently as a 46-kDa transmembrane protein known as Coxsackievirus and Ad receptor (CAR). 15 The subsequent event of virus entry into cells occurs via internalization into clathrin-coated vesicles 16 and is mediated by an Arg-Gly-Asp sequence in penton base protein, which binds to cellular integrins ␣ v ␤ 3 and ␣ v ␤ 5 . 17, 18 The penton base protein is also implicated in the release of the virus from endosomes. 19 -22 It has been suggested that the penton base undergoes an acid-induced conformational change in endosomes, resulting in the exposure of hydrophobic domains; this exposure, in turn, leads to the disruption of the endosomal membrane. 23 The detailed steps of Ad2 through the cellular entry pathway and the dismantling of virion particles include the release of fibers, the dissociation of the penton base structure, the degradation of core proteins and capsid-stabilizing proteins, and the transport of uncoated viral DNA into the nucleus. 24 
Viral replication cycle
Ad is a type of lytic DNA virus. The replicative cycle of Ad starts from entering cells and ends at release from the lysed, infected cells. The Ad lytic cycle with group C viruses (Ad2 and Ad5) is very efficient and results in ϳ10,000 virions per infected cell, 25 along with the synthesis of excess viral protein and DNA that are not incorporated into the virion. Each cycle takes ϳ32-36 hours; the early phase (with early gene expression) occurs for the first 6 -9 hours, and the late phase (with onset of viral DNA replication, late gene expression, and assembly of virions) takes the rest of the time. The whole replicative cycle does not require integration of the viral genome into host cell genome, nor has any integration mechanism been identified for Ad.
Viral DNA replication
Replication of Ad genomic DNA has been studied extensively, both in vivo and in vitro. 26 Ad-DNA replication starts at either end of the duplex genome, with semiconservative 1 U/two-way duplication from the 5Ј end to the 3Ј end. The process has no requirement for "Okazaki" intermediates. 27 The viral proteins involved in Ad-DNA replication are the 80-kDa preterminal protein (pTP) and a 140-kDa DNA polymerase (Ad-DNA Pol). The most unique feature of Ad-DNA replication is that the 55-kDa terminal protein (TP) is linked covalently to nucleotides 9 -18 of the 3Ј end sequences of each ITR. The special TP/ITR structure serves as the origin of the viral DNA replication. 28 This stabilizes viral DNA replication and maintains the independence of the viral replication machinery from that used for cellular DNA synthesis. This observation is critical, because biosynthesis in the infected cell is shut down during the late phase of viral infection. However, some cellular nuclear proteins (factors I and II) have been identified that are complementary to the initiation and elongation of Ad-DNA replication. 29, 30 Viral particle assembly Assembly of the Ad virion generally has been described as consisting of the following steps: (a) formation of the major structural unit of capsid, (i.e., capsomers of hexon and penton), (b) assembly of empty capsids, (c) insertion of viral DNA into capsids, and (d) proteolytic cleavage of maturation. 3 During this process, the encapsidation mechanism of viral genome into viral particles is the most critical step and is of interest for the development of Ad vectors. Similar to the cis-acting packaging domains of Ad16 and Ad3 that are located within the left 390 bp, 31, 32 the packaging signal of Ad5 is located in the left end of the viral genome (194 -380 bp) as seven AT-rich motifs of nucleotide sequences. 33 These A-repeat elements are functionally redundant, but follow a hierarchy of importance, with elements I, II, V, and VI as the functionally most dominant repeats. Deletion or manipulation of the A-repeats of the packaging signal resulted in attenuation or loss of packaging of the viral genome. [33] [34] [35] Additional studies on the packaging signal have demonstrated that additional sequence determinants are located in the identical position relative to A-repeats I-II and A-repeats V-VI (i.e., CG dinucleotides existing 11-bp downstream of the middle thymidine residue within the thymidine triplet). 36 Selection of revertants from a packaging-deficient Ad equipped with trimmed or synthetic A-repeats resulted in identification of the minimal A-packaging sequence (A-repeats V-VI-VII, 334 -385 bp) that exhibits maximal packaging activity. The experiments demonstrated evidence that A-repeats act as independent units, in which an Ad containing more A-repeats has a competitive advantage over viruses with fewer A-repeats. 36 Taken together with the finding that wt Ad packaging can be competed by an excess of packaging-domain sequences, it was proposed that a limiting trans-acting factor(s) exists that binds the A-repeats for encapsidation of the viral genome. 35, 36 It is not clear whether an Ad-DNA replication factor such as TP is involved in the Ad packaging process.
Mechanisms and methods of generating conventional (dLE1) Ad vectors
The size limit for DNA that can be packaged into Ad virions is quite close to the size of the wt Ad genome. The largest described Ad-simian virus 40 (SV40) hybrids are only ϳ2% larger than the Ad itself. Thus, the insertion of large foreign DNA into Ad would require the replacement of viral sequences. To make viable recombinant Ad (rAd) that can carry heterologous DNA fragments, the function of the replaced viral DNA has to be either dispensable or compensated through a transacting source. The trans-acting function actually functions as a helper, and can come from either helper virus, helper cells, or both. There are two types of current Ad vector systems based on different types of helper function.
The helper virus-dependent Ads were the early and original type of infectious rAd, which was gradually developed into a vector system for delivering heterologous genes since the discovery of Ad-SV40 hybrid viruses (to be discussed further in following section). This approach has a strong shortcoming because of helper virus contamination in the recombinant virus. Its development became even slower after a new approach to generating helper virus-independent and replicationdefective vectors was invented.
Helper virus-independent Ad vectors (dLE1-Ad) became possible because of the development of the first Ad-helper cell line, 293, which was derived from human embryonic kidney (HEK) cells by transformation with Ad5 DNA fragments and constitutively expresses E1 proteins. 37 With the trans-complementation by the E1 products in 293 cells, E1 substitution with foreign DNA or expression cassettes become possible. Three basic approaches have been developed for the generation of replication-defective and helper virus-independent rAd.
Three basic methods for generating rAds
The first method is the Stow method, 38 which is an in vitro ligation approach, using the modified E1 region with the most left end of the Ad genome to ligate with the isolated XbaI-large fragment of the Ad genome (3.7-100 mu) of dL309 and transfecting the artificial Ad genome into 293 cells for the production of new viruses.
The second method is an approach that uses intracellular homologous recombination between partial viral genomes. The method mixes the modified left arm of the Ad genome with a left-end-deleted Ad genome overlapping with the left arm (ClaI-large fragment, 2.5-100 mu) for cotransfection of the DNA into 293 cells, which generates an Ad vector through homologous recombination. 39 These two methods are similar in that they use isolated viral DNA and digest with restriction enzymes to obtain a left-endless large fragment of viral genome. Because of the cumbersome process of viral DNA purification and fragment preparation, the efficiency of the method is relatively low. Contamination of uncut wt viral genome is usually present, which makes the background of generating rAd relatively high.
The third method is an approach that uses plasmid recombination. 40 This method was developed based on the construction of an Ad genomic plasmid by inserting pBR322 into the XbaI site in the E1 region of a circularized wt Ad genome isolated from the Ad-infected cell lysate. 41, 42 This plasmid, known as pJM17, is too big to be encapsidated because of the insertion of the pBR plasmid sequence. Therefore, it can be used to cotransfect 293 cells with a smaller plasmid (shuttle vector) that contains the left-end arm of the Ad genome (0 -16 mu) with its E1 region substituted by the expression cassette of the transgene. rAd vectors are generated through homologous recombination between the shuttle and Ad-genomic plasmids in 293 cells (Fig 3) . This method has been developed further with improvement of both types of plasmids, particularly in deletion of the packaging signal and the E1 region with further removal of the residual sequences of the E3 region. 43 Among the three methods, the cotransfection of plasmids is the one that is easiest to grasp; in addition, this approach is repeatable, because of the easy preparation of highquality plasmid DNA. This method, which also generates a lower background of unwanted viruses, is most commonly used for the production of rAd vectors.
Other advanced methods for generating rAds There are also certain advanced methods for generating rAd vectors. For example, the homologous recombination process of the viral genome was the first to be performed in a selectable yeast artificial chromosome cloning system 44 or in a bacterial Escherichia coli cloning system. 45, 46 The rAd vector genome can then be transfected into 293 cells or other helper cells to propagate recombinant viruses. Using a site-specific recombination device such as the LoxP/cyclization recombination (Cre) system to enhance the formation of the rAd vector genome in helper cells is another example 47 in which the process of recombination to generate Ad vectors can be specifically designed to occur between two plasmids at the LoxP sites in the helper cells in which Cre protein is expressed. Another method that has been reported uses Ad-DNA/TP complex to cotransfect with an Ad-genome-bearing cosmid into permissive cells, the so-called "COS/TPC" method. 48 The fragmented Ad-DNA/TP complex, prepared from isolated Ad genome digested with EcoT22I or AseI/EcoRI, enhanced the efficiency of generation of rAd. A recent report described a similar method using a cosmid as an Ad vector-cloning system for the in vitro construction of full-length recombinant Ad. 49 Although these methods take additional skill and know-how as well as more construction steps to set up the working system, they usually provide certain advantages over the basic methods to obtain the desired rAd vectors with more effectiveness and efficiency.
Propagation, purification, quantitation, and assay development of Ad vectors The development of Ad vectors as potential therapeutic agents for multiple applications of in vivo human gene therapy has resulted in numerous preclinical and clinical studies. This makes it very critical to develop costeffective methods for the propagation and purification of research-scale or clinical trial-scale quantities of the vectors; standardized methods for quantifying or dosing the vectors; and various assays to determine the identity, purity, integrity, viability, infectivity, potency, stability, safety, toxicity, and therapeutic efficacy of the vectors. These methods or standards are not only useful to study and compare different or related vectors but are also required to approve and conduct clinical trials.
Methods for Ad vector propagation
Early wt Ads of different serotypes were generally propagated in human KB cells and HeLa cells. 50 The E1-substituted Ad vectors are usually propagated in monolayer cultures of classical 293 cells. 5 A subline of 293 cells that is able to grow in suspension culture was developed by passage of 293 cells through nude mice. 51 This new line, designated 293N3S, grows with a doubling time of ϳ30 hours and continues to express Ad5 E1 products. This cell type offers an alternative for the propagation of Ad E1-substituted vectors for large-scale production using bioreactors. Several new Ad-helper cell lines with different complementary capacities have been generated after 293 cells during the course of studies of Ad virology and the development of Ad vectors (to be discussed in following section). The variety of available cells for Ad propagation is indicative of the need to specifically design and adapt cells to certain conditions to meet the different requirements for vector production.
Methods for Ad vector purification
Simple and relatively crude methods for the isolation of Ad virions involve either pelleting the viral particles at 35,000 ϫ g or precipitating the virus with polyethylene glycol for low-speed centrifugation. Since the early 1960s, The classical method for the purification of wt Ad as well as rAd has been CsCl density-gradient ultracentrifugation. 52 Ad can be sharply banded in the such gradients and effectively purified from cell debris and empty viral capsids. For more than 30 years, this method has been well used, 5 mainly because it can provide highly purified and viable Ad. However, the purification process is relatively cumbersome, timely, and materially costly. It becomes impractical and inconvenient, particularly when large-scale preparations or manufacturing of the vector is needed. To overcome these limitations, a column chromatography method to purify Ad vector was tested. 53 The purity, viability, and infectivity of the rAd vector ACN53 (prepared using anion exchange, size exclusion, hydrophobic interaction, or metal-cheling resins) were compared with CsCl-gradient preparations by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blot analysis, absorbance spectrum, total particle to infectious particle ratio, expression of p53 gene product in Saos-2 cells, growth inhibition of Saos-2 cells, and contamination by 293 cellular proteins. The optimized process of this study was to combine the diethylaminoethyl and immobilized zinc affinity chromatography. However, the stepwise recoveries from these two columns ranged from 44% to 67%. The loss of the virus after each step was primarily due to selective pooling of the column fractions and physical trapping of virus in the column resin itself. 53 Salt concentration, ionic-charge level, and pH may also have affected the viability of the Ad. Thus, more efforts are needed to further develop the method for large-scale purification of Ad vectors.
Methods for Ad vector quantitation
The methods available for measuring Ad vector concentration can be divided theoretically and practically into biological methods and physical methods. The former rely on the infection of cells in culture followed by a quantitative determination of the biological functionality of the vector (e.g., plaque assay) 50 or histochemical or immunostaining of products of the reporter or effector gene delivered by Ad vector in targeted cells. 54 The latter methods involve physical measurements of viral particle or DNA quantity (e.g., by direct visualization by electron microscopy 55 or by measurement of the optical absorbance of the virion DNA). 56 Different concentrations or dose units of Ad vectors have been used, such as PFU, 50% tissue culture infective dose, infectious units, transducing units, particle units, etc.
With the rapidly increasing applications and studies of Ad vectors, a lack of standardization of the methods used to determine concentration with standardized units has often made a comparison of various results or data from different laboratories difficult or impossible. Recently, an intensive effort was made to systematically compare the methods and define the variables for quantification of the concentration of Ad vectors. 57 Optical absorbance measurement was found to be a simple and precise procedure, but accuracy was dependent upon physical disruption of the virion to eliminate artifacts from light scattering and upon the use of a correct value for the extinction coefficient. The biological assays for enumerating functional virions were highly dependent upon the assay conditions and, in particular, the time of virion adsorption and adsorption volume. Under optimal conditions, the bioactivity of the vector, which is defined as the fraction of total virions that leads to detected target cell infection, was determined to be 0.10 in the plaque assay and 0.29 in the gene transfer assay. 57 The difference is most likely due to the fact that detection by gene transfer only requires the measurement of levels of transgene expression in the infected cell, whereas plaque formation depends upon a series of biological events of greater complexity. These results showed that the exact conditions for the determination of infectious virion concentration and the bioactivity of rAd vectors are crucial and must be standardized for comparability.
Development of assays for Ad vectors
Before the application of Ad vectors for gene therapy, assay methods of wt Ad and rAd mainly covered the area of virological and functional study. 5, 50 Along with the wave of Ad development for gene therapy and vaccination, a multiplicity of diversified and innovative assay designs for application-oriented or regulatory-required vector assessment have thrived. All relevant assays associated with the development of the Ad vector for gene therapy of cystic fibrosis have provided a good history of how a systematic Ad vector assay methodology for the purpose of preclinical study and clinical trial support was performed.
5,50,55-57 Development of the assays for the Ad vectors carrying the p53 tumor-suppressor expression cassette is another good example. These assays have been developed not only to analyze and verify the virological, biochemical, and biological features of the vectors, but also to fulfill the collection of supporting data for the approval of the clinical trial protocol, to support the conduct of the clinical trial, and to develop the manufacturing process. 58 -61 Among the assays of Ad vectors, two types of assays are critical; one is used to determine physical purity, whereas the other is used to evaluate the contamination of replication-competent Ad (RCA). Analytical anionexchange high performance liquid chromatography has been used recently to analyze the purity of a given preparation of Ad vectors. 62 Assays for the determination of RCA have been developed for both biochemical and biological parameters. 60, 63, 64 Plaque assays to determine the replication competence of E1-substituted Ad vector were carried out on a human lung cancer-derived cell line, A549, which has no AdE1 gene and function but supports the growth of RCA. [63] [64] [65] Because the RCA depends upon acquisition of AdE1 gene and function, which are deleted from the replication-defective Ad vectors, detection of the presence of E1 sequence in a given batch of rAd vector preparation is a logical strategy. Southern blotting and polymerase chain reaction methods have been used for this purpose. 60, 64 For the polymerase chain reaction assay, the design of the assay included an internal viral sequence amplification control using two pairs of primers to amplify AdE1 sequence and vector backbone simultaneously; this control reached a sensitivity of detection of 1 PFU of RCA per 10 9 PFU of total vector input. 60 Biological assays for the detection of RCA were designed to detect the replication capability of rAd at the viral DNA level as well as virus. 59 The labeling of viral DNA with 32 P or consecutive infections with cell extracts in HeLa cells was used to determine RCA potential or the contamination of a given preparation of Ad-p53 vector. An additional development involved the application of A549 cells to determine RCA through a consecutive infection process using cell extracts that were initially infected with samples of the Ad vectors being tested. The benefit of using A549 cells is mainly that the cells have a high level of sensitivity and permissibility to Ad infection and replication.
Concerns of E1-substituted Ad vectors
The E1-substituted Ad (called the first generation) vector system is replication-defective and helper virusindependent. Generally, concerns regarding the first generation Ad vector for vector development are associated with the Ad virological features, the wt genome remaining in the backbone of the vector, and reliance on the complementation capability of the helper cell lines.
Limited gene delivery capacity. Because the E3 region is dispensable from the Ad genome, 66 the first generation Ad vectors, with the help of 293 cells, carry foreign DNA in either E1 or E3 or both regions. 5 In nature, Ad can package total DNA at ϳ105% of the wt genome, 67 providing capacity for an extra ϳ2 kb of DNA. Combined with ϳ6.5 kb of DNA, which is replaceable in the E1 and E3 regions, the maximum capacity of the current Ad vector is Ͻ8.5 kb, or ϳ23% of the maximal length of the vector. Approximately 82% of the wt Ad genome remains in the vector backbone. This predetermines a limited gene delivery capacity for the E1-and E3-deleted Ad vector.
Replication-competent Ads. The generation of RCA through multiple or scale-up propagation of the E1-substituted Ad vector in 293 cells can significantly affect evaluation of the outcomes of gene transfer experiments and may cause risks to patients. Emergence of a replication-competent subpopulation in the rAd stock may result mainly from two types of possibilities: generation from endogenous source or contamination from exoge-nous source. The former is theoretically possible through homologous recombination of the overlapping sequences between the rAd vector and 293 cells that contain the left-most 12% of Ad5 genome, 68 which can lead to the replacement of the expression cassette of the vector by an intact E1 region. This suggestion is supported by the finding that the RCA obtained from the propagation of E1-containing Ad vectors still carried the original E3 deletion. 65 Similar observations have been reported for Ad recombinants. 69 In one of the Ad vectors (CMVlacZ), the ratio of RCA to the vector was shown to progressively increase along with the propagation of the vector. After the first detection of RCA (passage 15), the titer of RCA increased rapidly. 64 It has been suggested that RCA has a replicative advantage over rAd vector because of better regulation of early gene expression. 5 This limitation strongly demands for improvements over the first generation Ad vector systems, and for the development of a new Ad-helper cell line in particular.
Immunogenicity of Ad vectors. Similar to other pathogen-induced host immune responses, resistance to infection as well as the elimination of Ad vectors and the attenuation of gene expression after gene transfer in recipient animal models were shown to result from three types of host defense mechanisms: innate, humoral, and cellular immune responses. These depend upon the site of delivery, the vector design, the species of the model system, the strain of virus, the immunological status of the host, and the nature of the transgene. 23,70 -75 A significant problem of first generation Ad vectors is that deletion of the E1 genes is not sufficient to completely ablate the expression of other E and L viral genes or to prevent the replication of viral DNA. It was shown that deletion of E1 could be overcome in vitro with high multiplicities of infection (MOIs) or through the action of cellular factors with E1-like activity. 76 -78 The expression of viral proteins and transgene products in Ad vector-transduced cells can stimulate destructive cellular immune responses, which leads to the coordinate loss of transgene expression and to the development of inflammation. Support for this observation has been derived from experiments performed in the nonhuman primate lung, 79 mouse lung, 80 liver, 71, 81 spleen, 82 and cotton rat lung. 83 Ad vector-induced cellular immune responses clearly require redesign of the Ad vectors to eliminate the sources of the problem, although it was demonstrated that Ad vector-infected cells could escape Ad antigen (Ag)-specific cytotoxic T lymphocyte (CTL) killing in vivo. 84 In this study, an E1-substituted Ad vector expressing human ␣1-antitrypsin (␣1AT) administered by intravenous (i.v.) injection did stimulate an Ad-specific cellular immune response; however, the response failed to abolish vector-directed gene expression in vivo.
Several animal experiments have demonstrated that the humoral responses of the recipients against Ad vectors could form a protection barrier by neutralizing the vector particles, which is particularly effective on secondary entry and delivery of the vector. 85, 72, 74 When rhesus monkeys treated at intervals of ϳ3 weeks with 15 or 17 instillations of Ad2/CFTR-2 were challenged with an Ad vector of Ad2/␤-gal-2, the level of ␤-galactosidase (␤-gal) expression was dramatically lower than that detected in control monkeys treated with Ad2/␤-gal-2. 85 A similar decrease in transgene expression following two administrations of Ad vector has been observed in the mouse, 71 rat, 86 and cotton rat 72 and is attributed to the development of neutralizing antibodies (Abs) against the virus. In the cotton rat, the level of transgene expression was shown to be inversely correlated with sera titers of Ad-neutralizing Abs. 72 In the clinical trial of Ad-mediated gene therapy of cystic fibrosis, an increase in the titer of anti-Ad Abs was detected by complement fixation and/or enzyme-linked immunosorbent assay. 87 The highest titers were observed in the sample of the patient who received the highest vector dose. However, no increase in titers of anti-Ad neutralizing Abs above pretherapy levels was detected in any individual following AdCFTR administration.
The innate immune response of the host to abolish Ad vectors immediately after infection may contribute to loss of the vector from infected tissue. A study directed toward evaluating the early phase of host response to the Ad vector genome in the mouse liver was designed to focus on the first 24 hours following in vivo administration, 75 a time frame during which specific anti-Ad immune responses have not yet been initiated. 88, 89 The results demonstrated that innate immune processes caused a significant loss of the Ad vector genome from the liver within 24 hours following administration, and suggested that the rapid, innate immune clearance of the Ad vector genome might be a much more dominant mechanism of removal of the vector genome than the adaptive immune-related clearance that occurs over subsequent days to weeks. 75 However, whether human recipients will have similar innate immune responses needs to be further determined.
Both of the innate and humoral immune responses studied thus far revealed certain limitations of the Ad vectors that may affect the potency and readministration of Ad vector for gene therapy of cancer; however, the reactions of the host against Ad vectors, particularly the viral infection-induced local infiltration of lymphocytes, may be used to enhance the induction of specific anticancer immune responses.
APPLICATION OF Ad VECTORS IN CANCER TREATMENT
Gene therapy for cancer Th application of Ad for cancer therapy can be dated back to the 1950s, when wt Ad was used to treat cervical cancer. 90 Because of high infectivity, cytotoxicity, and immunogenicity, Ad vectors have been very useful in the development of novel anticancer medicines. The application potential of rAd for gene therapy of cancer has been rapidly explored with several strategies. 91 In addi-tion to the immunostimulating genes for tumor vaccination, Ad vector-mediated delivery of tumor-suppressor genes, antisense oncogenes, suicide/toxin genes, and other effector genes have been successfully demonstrated to be effective in inducing tumoricidal effects and anticancer immunity in different animal models. 92, 93 The following methodologies are examples that represent certain possibilities for breakthroughs along this direction of research and development, including the development of new tumor-specific replicative Ad vectors.
Tumor-suppressive Ad vectors. This type of Ad vector carries tumor-suppression genes. The p53 gene is one of the most frequently characterized tumor-suppression genes. 94, 95 Mutations in the p53 gene and subsequent loss of functional p53 protein have been implicated in the malignant behavior of a variety of human tumors. 96, 97 Transduction of the wt p53 gene into cancer cells by transfection or retroviral-mediated gene transfer demonstrated the suppression of cancer growth in vitro and tumor formation in animal models. 98, 99 To achieve a high efficiency delivery and a high level of expression of the p53 gene in lung cancer cells in vivo, an E1-substituted recombinant p53 Ad (Ad5CMV-p53) was generated. 100 Human non-small cell lung cancer cell lines representative of different p53 configurations were used to evaluate the expression of the Ad5CMV-p53 virus. In the H358 cell line, which has a homozygous deletion of the p53 gene, infectivity of Ad5CMV-p53 was 95-100% at an MOI of 30 -50 PFU/cell, as detected by immunohistochemical analysis. Western blots showed that the p53 protein was expressed at a high level in Ad5CMV-p53-infected cells. Growth of the lung cancer cells containing p53 deletions or mutations was greatly inhibited by Ad5CMV-p53, whereas growth of the cell line containing wt p53 was less affected. Tumorigenicity tests in nude mice demonstrated that Ad5CMV-p53 suppressed tumor formation. 58 Induction of apoptosis was shown to be one of the mechanisms for the tumoricidal effect of Ad5CMV-p53. 101 Ad-mediated p53 gene transfer has also been demonstrated to be effective in suppressing tumorigenicity in different animal models. 102, 103 Clinical trials of Ad-mediated p53 gene transfer for the treatment of lung, head and neck, and liver cancers are ongoing. The phase I results of the head/ neck and lung cancer trials reported at the 1997 American Society of Clinical Oncology meeting in Denver were quite promising.
The p16 gene, which is also known as the major tumor-suppressor-1 gene, was isolated and characterized during the studies of Adp53. 104 Soon after, the p16 gene was applied to the same vector construct as that of Adp53. 105 The p16 protein belongs to a newly described class of cyclin-dependent kinase-inhibitory proteins that also includes p15, p21, and p27. The p16 gene maps to chromosome 9p21, a region frequently deleted in many tumor types. Homozygous deletions and mutations of the p16 gene are frequent in human tumor cell lines. The Ad-p16 vector was tested in serial lung cancer cells and animal tumor models. Expression of the introduced p16 blocked tumor cell entry into the S phase of the cell cycle and inhibited tumor proliferation both in vitro and in vivo in contrast with control viral vectors. 105 Additional experiments using this therapeutic approach were performed by combining Adp53 and Adp16 in the treatment of mouse hepatocellular carcinoma models. 106 A synergistic effect of p16 and p53 on the induction of apoptosis was observed. It was reported that combinational transduction of p16 and p53 genes by Ad vectors led to the efficient induction of apoptosis, which could not be achieved by p53 alone in Rb ϩ cells expressing either normal or mutant p53. Injection of a mixture of Ad-p53 and Ad-p16 (each at half the amount used for the controls) in established nu/nu xenographic hepatocellular carcinoma (Huh7) models resulted in a complete block of tumor growth for Ն12 days, whereas Ad-p16 had some effect and Ad-p53 had a marginal growth-retarding effect. It was suggested that Ad-p16 induced inactivation of the product of the retinoblastoma susceptibility gene, pRb, which may then enhance Ad-p53-induced apoptosis in cancer cells. 106 An alternative approach to the delivery of tumorsuppressor genes is to transfer antisense oncogenes into tumor cells. 93 Suppression of the transcription or translation of proto-oncogenes or oncogenes by antisense RNA has been successfully demonstrated on c-fos, 107 c-myc, 108 and k-ras, 109 leading in each case to reversion of the transformation phenotypes of the target cells. An anti-k-ras rAd was generated to deliver a 2-kb k-ras genomic fragment into H460a lung cancer cells. 110 The antisense RNA was expressed at high levels in the vector-infected cells. The growth of H460a cells that possess a codon 61 k-ras mutation was inhibited by 47% in monolayer cultures and by 90% in the colony-formation assay. At a similar level of transduction in the cell line H358 (which contains a codon 12 k-ras mutation), a 59% inhibition of monolayer growth was observed compared with control vectors; however, the growth inhibition of H322 cells (wt k-ras) was no different from control vector-infected cells.
Prodrug/drug-sensitizing Ad vectors. This type of therapeutic approach is known as virus-directed enzyme prodrug therapy. 111 The strategy is based on the theoretical concept that reduction of the systemic toxicity associated with chemotherapeutic agents or enhancement of the local therapeutic effect might be achieved by transducing tumors or surrounding tissues with the genes encoding a prodrug enzyme that can convert systemically administered nontoxic agents into cytotoxic or genotoxic agents and induce an associated therapeutic effect such as the "bystander effect." The principle of this approach has been shown in several systems by transferring or transducing the gene for a relevant prodrug enzyme to tumor cells in vitro and then demonstrating the suppression of growth of the genetically modified cells in vitro and in vivo. [111] [112] [113] [114] [115] [116] [117] [118] Herpes simplex virus-thymidine kinase (HSV-tk) is the most representative prodrug enzyme studied thus far; HSV-tk converts the nontoxic nucleotide analog ganciclovir (GCV) into a phosphorylated compound that acts as a chain terminator in DNA synthesis, selectively killing dividing cells. The therapeutic efficacy of Ad-mediated HSV-tk gene after in vivo transduction of rat C 6 glioma cells followed by GCV administration was studied in tumors generated in the brains of nude mice. 119 After 8 days of tumor growth, 3 ϫ 10 8 Ad/Rous sarcoma virus (RSV)-tk viral particles were injected into the tumors, and the mice were subsequently treated with GCV for 6 days. When compared at 20 days after tumor implantation, the mean cross-sectional area of the tumors in the treated animals was 23-fold smaller than in control animals and the tumor volume was reduced by Ͼ500-fold, demonstrating the potential of intratumoral (i.t.) delivery of a prodrug gene with the Ad vector. In another brain tumor model, i.t. injection of the same Ad/RSV-tk followed by the systemic administration of GCV suppressed the growth of tumors in syngeneic rats and supported a significantly longer time of survival in contrast with Ad-␤-gal plus GCV treatment as a control. 120 Application of the cytosine deaminase gene for a prodrug Ad vector is another example. Mammalian cells do not produce cytosine deaminase, but the enzyme is found in a variety of bacteria and fungi. 121 This enzyme can deaminate 5-fluorocytosine (5-FC), a drug used to control fungal infections, to 5-fluorouracil, a chemotherapeutic agent used to treat carcinomas of the colon, rectum, breast, stomach, and pancreas. The cancer cells engineered with the cytosine deaminase gene have been shown to have increased sensitivity to treatment with 5-FC either in vitro or in vivo. 115, 116, 122 To transduce the cytosine deaminase gene effectively to the tumor, an Ad vector was chosen for construction of AdCMV.CD. One of the key issues in this approach is the effective targeting of the prodrug vector to the tumors. Progress has been made in targeting infectious recombinant viral vectors to cells through cellular surface receptors with genetic or biochemical modifications of the viral surface. An alternative strategy is to target cancer cells at the transcriptional level using lineage-specific promoters that restrict expression of effector genes to tumor cells but not the related normal cells derived from the same developmental lineage. 124 Ad-based vectors. The strategies for designing the anticancer Ad vectors described above all used replicationdefective E1-substituted Ad, which did not fully explore the potency of Ad mechanisms. However, application of the degenerative effects of viruses for treating cancer has been practiced since the start of this century, when rabies vaccination was thought to modify favorably the course of cervical cancer. 135 The lytic potency of Ad prompted it to be considered as a candidate cancer therapy agent. 90 Wt live human Ads were first tried in the treatment of cervical cancer right after discovery of the viruses in 1953. 136 Large amounts of virus were given to patients through i.t., intra-arterial, or i.v. inoculation. Of the patients treated, 65% had responses as measured by necrosis of cancer tissue. No appreciable illness or other significant clinical effects were observed. Autopsy findings confirmed the clinical observations that the injected virus produced only local effects on the cervical tumor and did not affect the progressive growth of tumors in the pelvic tissues or the development and growth of metastases. 90 Two other recent approaches using Ad-based vectors exploited the interaction of AdE1 region proteins with cellular proteins and their ability to induce target cell apoptosis. AdE1A protein has been shown to be able to induce apoptosis in cultured cells. 137, 138 This protein was also shown to suppress the expression of the HER-2/neu proto-oncogene in cancer cells. 139 The HER-2/neu gene is frequently amplified or overexpressed in different types of human cancers and correlates with a shorter survival time or lower survival rate in ovarian cancer patients. Based on these observations, a strategy to use E1A as a therapeutic gene to treat ovarian cancers that overexpress HER-2/neu was developed. 140 To evaluate the potential treatment of HER-2/neu-overexpressing lung cancer with E1A, an Ad5-E1A vector, Ad.E1A ϩ , was used to transduce the E1A gene into HER-2/neuoverexpressing as well as low-expressing human lung cancer cell lines and corresponding mouse tumor models. 141 Ad.E1A ϩ suppressed HER-2/neu overexpression and inhibited i.t. lung cancer growth in animals. In contrast, no significant effect was observed on the HER-2/neu low-expressing cell line and its tumor formation.
The human AdE1B gene encodes a 55-kDa protein (p55) that binds and inactivates the tumor-suppressor p53 protein. This binding is essential to Ad replication, possibly because E1A induces p53-dependent apoptosis. It was hypothesized that an Ad mutant that does not produce E1B p55 should be unable to replicate in normal cells but would be able to replicate in cells lacking functional p53. The dl1520 virus is such a mutant. This human group C Ad contains an 827-bp deletion in the AdE1B region and a point mutation at 2022 bp of the Ad genome, resulting in a stop codon that consequently prevents the expression of a truncated protein from the deleted gene. 142 Subsequent experi-ments demonstrated that dl1520 was able to replicate and lyse p53-deficient human tumor cells, whereas the cytopathic effects of the virus were reduced by approximately two orders of magnitude in the cancer cell line expressing normal p53. 143 It was reported that normal human cells were highly resistant to the dl1520-mediated, replication-dependent cytolysis. In contrast, a wide range of human tumor cells, including numerous carcinoma lines with either mutant or normal p53 gene sequences (exons 5-9), were efficiently destroyed. Antitumoral efficacy was documented following i.t. or i.v. administration of dl1520 to nude mouse-human tumor xenografts; the efficacy of dl1520 in combination with chemotherapy (cisplatin, 5-fluorouracil) was significantly greater than with either agent alone. 144 Tumor-specific replicative Ad vectors. All of the strategies of virus-mediated gene therapy for cancer described above have certain limitations in therapeutic efficacy and are not particularly satisfactory for achieving quantitative and exhaustive infection of the entire local tumor mass. This is because the eradication of tumor cells by these methods depends upon directly hitting the target cells, although a limited bystander effect may help to suppress or kill the surrounding uninfected cells. However, without significant local amplification mechanisms, optimal vector delivery and subsequent tumor killing will not be obtained. A strategy to circumvent such limitations would be to design an Ad vector that could amplify and, within the tumor, transduce despite suboptimal anatomical or delivery-related conditions in the solid tumors. One such new approach is through the use of tumor-specific replicative Ad vectors. In this context, an RCA would be used to replicate selectively within transduced tumor cells, leaving normal tissues unaffected. Production of progeny virions from the transduced tumor cells would then allow the infection and killing of neighboring tumor cells.
Using ␣-fetoprotein (AFP) promoter/enhancers to control the E1 region, an Ad vector was designed that was capable of inducing a virus-mediated oncolytic effect on hepatocellular carcinoma. 145 As proof of concept for the first generation of tumor-specific RCA vectors, a modified version of the AFP promoter was used to replace the promoter of the E1A genes of a wt Ad. The vectors were shown to replicate in two of three human hepatocellular carcinoma cell lines that expressed high levels of AFP and killed ϳ500 -1000 hepatocellular carcinoma cells per virion particle in a 13-day assay. Little to no replication was observed in two other liver cell lines, two lung cancer cell lines, one colon cancer cell line, one cervical cancer cell line, and all human cell lines that did not produce AFP. In addition, the investigators tested two primary cultures of normal human lung epithelial and endothelial cells for replication of the vectors, because lung tissue is the primary target for Ad replication in humans. Neither primary culture supported any replication of the vectors, demonstrating the specificity of the vectors in cancer cell killing. 145 The investigators also proposed using other tumor-specific promoter/enhancers to treat different cancers with the same type of design as the tumor-specific vector.
A similar design of the tumor-specific replicative Ad using the prostate-specific Ag (PSA) promoter demonstrated the potential of this approach. 146 PSA is a widely used marker for the diagnosis and management of prostate cancer. The virus, called prostate attenuated RCA (ARCA), was constructed such that the minimal enhancer/promoter derived from the 5Ј-flanking sequence of the human PSA gene has replaced the Ad5E1A promoter. Infection of the prostate ARCA vector resulted in a high level of expression of E1A proteins in PSA-producing LNCaP cells, but not in DU145 cells, which are human prostate cells that do not express PSA. The titer of the prostate ARCA vector was significantly higher in LNCaP cells compared with several human cell lines that do not produce PSA (HBL100, PANC-1, MCF-7, DU145, and OVCAR3). Furthermore, in LNCaP cells, the yield of the virus was dependent upon exogenous androgen (R1881). The prostate ARCA vector destroyed large LNCaP tumors (1 ϫ 10 9 cells) and abolished PSA production in nu/nu mouse xenograft models with a single i.t. injection. 146 
Applications in vaccine development
The use of Ad to develop vaccines underwent several stages; from that of using inactivated wt Ad, to the use of live wt Ad, to rAd expressing other viral Ags, and subsequently to the use of rAd for cancer vaccines. The former two applications are intended to elicit an immune response from the host against Ad based on the pathogenicity of certain serotypes of Ad such as Ad4 and Ad7 that cause acute respiratory disease in military trainees. [147] [148] [149] The latter two applications, on the other hand, are designed to use the capability of Ad as a vector with high infectivity and a high level of foreign gene expression. 150 Inactivated or live wt Ad vaccines. Between 1958 and 1962, several field trials of inactivated Ad preparations produced a wide range of results. The immunity induced by the inactivated Ad varied from 70% to essentially nil. 151 Early trials were conducted by the military using vaccines made from types 3, 4, and 7 that were grown in monkey kidney tissue culture. The vaccines were considered "useful but not completely satisfactory." Soon after (in 1963), it was evident that, similar to polioviruses, Ads could proliferate in the gut and that protective Abs could then be produced. 152 Early studies concentrated on tests with Ad type 4, which was grown in HEK cell culture. Later, type 7 was also required and was evaluated. 153 Vaccines consisting of live Ad4 and Ad7 in enteric-coated capsules were licensed in 1980 for oral administration to military personnel. With nearly 14 years of extensive testing before licensing as well as a decade of subsequent use, the safety, immunogenicity, and efficacy of these vaccines have been well established. 153 Seroconversion rates after vaccination range from 50% to 100% for both Ad4 and Ad7, averaging ϳ80%, and immunization programs with these vaccines reduced epidemic acute respiratory disease infections due to Ad4 and Ad7 by 80%. 153 Throughout the course of wt Ad vaccine development, safety validation of the vaccines was of more concern than the demonstration of efficacy, because of the potential oncogenicity of Ad. However, the oncogenic activity of Ad could be demonstrated only in certain newborn animals, usually hamsters. Tumors were produced if animals were inoculated within the first 1 or 2 days of life or somewhat later if their immune responsiveness could be retarded. It was also shown that most Ad strains could "transform" cells in tissue culture. Such transformed cells produced tumors only when they came from strains of virus that were directly oncogenic. 154 The use of live Ads as oral vaccines for ϳ30 years in millions of military recruits without any significant attributable complications would seem to be affirmative proof of the safety of human Ads as recombinant vaccine vectors.
Although Ad4 and Ad7 have been used extensively as live vaccines in adults, Ad5 and perhaps other Ad serotypes in subgroup C may be better suited as vectors for the development of rAd vaccines, particularly for use in children. Unlike Ad4, Ad7, and Ad41, of which some variants have been linked to a number of serious complications in respiratory or gastroenteric infections, 155 infection with Ad5, although more frequent in children Յ5 years of age, is not generally associated with serious illness. In most cases, infection is limited to the upper respiratory tract with or without fever. Retrospective sampling studies of Ab titers to Ad5 show that, depending upon the geographic region, from 50% to ϳ100% of the population over the age of 5 years have been infected with Ad5. 156 Therefore, taking into consideration the hundreds of millions of naturally infected individuals and the fact that no significant mortality has been linked to Ad5, it seems that Ad5 may be a remarkably safe vector, even in an entirely unattenuated form.
rAd vaccines Development of a hepatitis B virus vaccine is a good example of using a rAd to generate anti-hepatitis viral vaccine. Sequences encoding HBsAg, the major envelope protein, have been substituted either for the E1 or E3 regions or between the E4 region and the right ITR. 150 The potential for vaccine development using Ad vectors has also been explored using HIV envelope protein, 157 measles virus hemagglutinin, 158 and HSV gB glycoprotein. 159 More research and development with regard to Ad-mediated viral gene vaccination was performed with different genes of interest, different types of Ad vectors, and various recipient host animals. 160 Although the results are variable depending upon the inserted gene and the ability to test the results in vivo, it is clear that animals can be immunized using Ad vectors. Some of these animals have been protected successfully against challenge with the virulent parent virus from which the immunizing gene was obtained. However, it was usually not efficient to reintroduce the same Ad vector for a booster response, mainly due to Ad-induced neutralizing Abs directed against the fiber and hexon in infected recipients. This is not dissimilar to a variety of live vaccines, including poliovirus, measles, and rubella, that are used currently in humans.
Anti-cancer Ad vaccines.
One additional development of rAd vaccines was to apply the vectors to design cancer vaccines. The approaches include induction of anticancer immunity through the delivery of either immunomodulatory genes or the genes of tumor-specific Ags by Ad vectors. Either approach uses the intrinsic immunogenicity of Ad vectors to enhance the elicitation of anticancer immunity.
Many cytokines can mediate anticancer activity in vitro and in vivo. 161 Interleukin-2 (IL-2) is a critical and potent cytokine, the pleiotropic effects of which include stimulation of the cell-mediated killing activity of CTLs, 162 enhancement of natural killer cell activity, 163 induction of lymphokine-activated killer cells, 164 and activation of tumor-infiltrating lymphocytes. 165 Although systemic administration of relatively high levels of recombinant IL-2 has led to the development of antitumoral immunity in animal models, it has achieved limited success in clinical trials 166 due to severe side effects resulting from a systemic administration of high doses. Thus, IL-2 has been of limited use for in vivo treatment of cancer patients. One strategy to circumvent this limitation is to generate a high concentration of IL-2 locally at the tumor site. Ad vectors carrying the IL-2 expression cassette (AdIL-2) were a natural choice for anticancer experimental designs as well as other approaches using IL-2-secreting tumor cells, such as ex vivo tumor vaccines or alternative gene delivery methods. 167, 168 The expression cassettes for IL-2 were driven by either a cytomegalovirus or an RSV promoter. Most tumor cell lines infected in vitro with AdhIL-2 or AdmIL-2 vectors at 10 -300 MOIs produced biologically active IL-2 at 0.1-2 g/10 6 cells/day. 92, 169, 170 An i.t. injection of AdIL-2 at 2.5 ϫ 10 8 , which resulted in Յ2 ϫ 10 6 PFU per 5-to 10-mm tumor induced ϳ50% tumor regression in a transgenic mouse model of mammary adenocarcinoma or in a syngeneic mouse hepatocellular carcinoma model. 92, 170 Eliminating existing tumors in this way resulted in immunity against a second challenge with the tumor cells. In another study using a mouse subcutaneous fibrosarcoma model, lower viral doses were ineffective and higher doses resulted in animal death due to IL-2 toxicity, possibly by leakage of viral vectors from the injected tumor and systemic distribution. 169 Ad vectors have also been used to construct tumor vaccines with other cytokines and immunostimulating factors such as IL-12 and costimulatory factor B7. [171] [172] [173] IL-12, also known as natural killer cell-stimulatory factor or cytotoxic lymphocyte maturation factor, appears to play a central role in the production of T helper type 1 immune responses. 174 Similar to IL-2, high-dose systemic administration of IL-12 can cause severe toxicity to patients. Local delivery of IL-12 using Ad vector is an obvious alternative. 171, 172 A high level (600 -800 ng/ tumor) of expression of IL-12 was detected after the AdmIL-12 was injected i.t. into mouse tumor models.
This produced tumor regression in Ͼ75% of the treated tumors. The interferon-␥ concentration was markedly increased within the tumor following AdmIL-12 administration, demonstrating that IL-12 was acting locally.
The B7 ligand is a costimulatory molecule that is expressed on activated B cells and other professional Ag-presenting cells, such as macrophages and dendritic cells (DCs). 175 In a mouse system, introduction of the costimulatory molecule B7-1 into tumors can increase antitumor immunity and eradicate tumor growth. 176, 177 An Ad vector was used to deliver the human B7-1 gene into established cancer cell lines and freshly resected cancers. 173 The infected cells were shown to express the B7-1 molecule on cell surfaces, which suggests the potential usefulness of Ad for engineering autologous tumors as tumor vaccines.
The recent recognition that many solid tumors possess tumor-associated Ags (TAA), which can be recognized by T cells, has opened the possibility for tumor Ag-based vaccination. 178 -180 The development of Ag-specific tumor vaccines using Ad vectors was attempted with melanoma-specific Ags, MART-1, and glycoprotein 100 (gp100). 181 Infecting the non-Ag-expressing HLA-A2 ϩ cell lines A375 and MDA-231 with the Ad2CMV-MART1 and Ad2CMV-gp100 vectors resulted in recognition by Ag-specific CTLs as demonstrated by specific target cell lysis and the release of cytokines including interferon-␥, tumor necrosis factor-␣, and granulocytemacrophage colony-stimulating factor. Immunizing C57BL/6 mice with these rAds demonstrated that Ad2CMV-gp100 could protect mice from murine melanoma B16 challenge administered intradermally. Deleting CD8 ϩ and CD4 ϩ T cells in vivo from Ad2CMV-gp100-vaccinated mice eliminated the protective effect. Thus, the anti-gp100 T cells induced by Ad2CMV-gp100 vaccination seem to be responsible for the protection.
An alternative approach is to use DCs, which have been evaluated as carriers, to deliver TAA for cancer gene therapy. 182 DCs are "professional" Ag-presenting cells that provide all of the signals required for the activation of both CD4 ϩ and CD8 ϩ cells. Using an approach that differed from the the previous studies on delivery of TAA by Ad vectors for immunization against murine tumors, 181,183 a recent study applied Ad vectors to transduce DCs with various genes, including tumor Ag. 184 It was found that 90% of murine bone marrowderived DCs could be infected with an Ad vectorexpressing ␤-gal gene and still retain their physiological and phenotypical characteristics. Furthermore, it was demonstrated that transgene expression was detectable in the spleen for Ն3 days following i.v. injection of Ad-transduced DCs. Using a polyoma middle T (PymT) transgenic murine mammary carcinoma model, the study further demonstrated that a single injection of 10 5 -10 4 ϫ 10 6 DCs transduced with an Ad vector expressing PymT provided complete and specific protection against tumor cell challenge in 100% of vaccinated animals. Immunization against the PymT tumor by injection with the PymT-expressing Ad vector alone resulted in varying degrees of effectiveness; this effectiveness was highly dependent upon the route of administration and led to a significant hepatic toxicity that was not seen in mice immunized with DCs transduced with the Ad vector.
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DEVELOPMENT OF LARGE-CAPACITY Ad VECTORS
Development of new Ad-helper cell lines and related vectors As a part of a replication-defective and helper-independent Ad vector system, the helper cell line is an obvious target for reformation. Generally, the task is to enhance the capacity of trans-complementation of the cells by placing more Ad genes or genomic regions in the cells. Successes along this line of attempt may provide several important benefits for the development of a new Ad vector, such as an increased gene-carrying capacity, a decreased possibility of generating RCA, and reduced vector immunogenicity. However, the current challenges are how to avoid viral protein-induced cytotoxicity while temporally supplying adequate complementation compatible with the natural process of Ad propagation in the new helper cell lines.
E1-complementing cell line.
The first AdE1-complementing cells were 293 cells, which were generated through immortalization of HEK cells by sheared Ad5 DNA. 37 This cell line constantly expresses the E1 region products and has served as a valuable resource to study Ads and the development of Ad vectors. However, the cells have approximately five copies per cell of the left 12% of the viral genome and approximately one copy per cell of 9% of the right end of the viral genome. 68 Therefore, the cells can provide Ad vectors with a complementing genetic background that can lead to homologous recombination due to the overlap of sequences in the vector backbone and reversion back to RCA. 64, 69 Consequently, 293 cells are not suitable for large-scale production of clinical-grade material because batches are frequently contaminated with RCA.
A new E1-complementing cell line was constructed by the transformation of human embryonic retinoblasts with a plasmid containing 79 -5789 bp (E1 fragment) of the Ad5 genome. 185 The established cell line, called 911, exhibited several characteristics in common with 293 cells, such as high transfectability and similar frequencies of homologous recombination. In addition, the 911 cells perform faster in plaque assays and yield Ad vector production that is up to three times as high as that achieved with 293 cells. 185 Another construct used a constitutive or GAL4-inducible expression plasmid to deliver a trimmed E1 fragment (base pairs 505-4034 of the Ad5 genome) into A549 cells, 186 an Ad-susceptible human lung carcinoma cell line. 65, 187 E1A transcription was elevated in most of the cloned cells, although the level of E1A expression was not found to correlate with the efficiencies of complementation. The E1B 55-kDa protein did not seem to be required for the complementation of E1-deleted Ad vectors. It was not apparent whether this could affect the efficacy of complementation of the A549 clones toward E1-deleted viruses, although the amplification yields obtained with these new complementation cell lines were lower than with 293 cells. 186 The advantage of these new cell lines over 293 cells has to do with the fact that the chance to generate RCA has been reduced.
E2A-complementing cell line. As a genetic system for the isolation and propagation of Ad mutants containing lesions in the E2A region, stably transfected HeLa cell lines were developed that express an integrated copy of the gene encoding the multifunctional Ad-DNA-binding protein (DBP) under control of a dexamethasone-inducible promoter. 188 With these cells (gmDBP) several novel E2A mutant Ads (Ad5 dl801 through Ad5 dl805) were generated through mutagenization of a cloned E2A gene in vitro and introduction of the mutated E2A into the viral genome by in vivo recombination. 189 Because these cells did not allow severely defective viruses to form plaques, additional gmDBP cell lines were constructed that allowed all DBP-negative mutants to form plaques. 190 Studies of E2A cell construction and E2A mutant viruses provided a good example with regard to the development of artificially designed rAds and their complementing cell lines.
E4-complementing cell line.
To extend the advantages of complementing cell systems to the study of regions of the Ad genome that are not directly involved in cell immortalization, such as the E1 region, a cell line was established by the introduction of the right-hand terminal Ad5 EcoRI restriction fragment (83.5-100 mu, containing all of E4) into Vero (African green monkey kidney) cells. 191 The E4 fragment carried by a plasmid vector (pSV2gpt) was transfected into Vero cells by calcium phosphate precipitation. The functional cell line that was cloned as a result (W162) permitted plaque formation by H2 dl808 at an efficiency that is Ͼ106-fold higher than that of the parental Vero cells and allowed the production of high-titer, helper-free H2 dl808 stocks. With this cell line, many E4 deletion mutants were generated and studied. 192 Again, these early studies provided the strategy and methodology for the development of Ad vector helper cell lines.
E1-and E2-complementing cell line.
An E1-and E2A-complementing cell line was constructed by introducing the two regions under separate glucocorticoid-responsive promoters into A549 cells. 193 The cell line, AE1-2a, supported the generation and propagation of a rAd vector, Av3n␤g, that has deletions in AdE1, AdE2A, and AdE3 regions and carries a ␤-gal reporter gene cassette. Characterization involved a comparison of Av3n␤g with Av1n␤g, which is an E1-and E3-deleted vector, and with Av2Lu, which is a vector with an E1 deletion and a ts125 mutation in E2A. The E1/E2A-deleted vector was shown to have reduced cytotoxicity and less leakage in both viral gene expression and replication even at higher MOIs, in contrast with the Av1n␤g and Av2Lu vectors.
A similar approach was taken to construct an E1-and E2A-complementing cell line by transfecting a 5.9-kb fragment of Ad5 E2A region with its E and L promoters into 293 cells. 194 The cell line, designated 293-C2, expressed E2A mRNA and protein and was found to complement an E1-and E2A-deleted vector, although the titers of the vectors were 10-to 30-fold lower than that of the vectors with the wt E2A region. Vectors carrying the ␤-gal or human ␣1AT expression cassettes were shown to effectively deliver transgene into mouse liver via i.v. injection. The duration of transgene expression was brief for C3H/J and CBA/J mice but was prolonged for C57BL/6J mice. 195 Disappearance of human ␣1AT from the blood was correlated with the appearance of Abs. Dosage studies indicated that the persistence of expression of human ␣1AT could be markedly decreased by the administration of high doses of the vector in a manner consistent with a nonimmunemediated toxicity following injection. 195 Several cell lines complementing the E2B region have also been developed and characterized. 196 -198 HeLa and 293 cells were transfected with a plasmid containing pTP cDNA driven by the tetracycline-regulated promoter and the neomycin phosphotransferase gene driven by the SV40 early promoter. 196 The cloned cell lines expressed pTP at a wide range and permitted the growth of a ts TP mutant virus, H5sub100, at the nonpermissive temperature. Another cell line that complements Ad-DNA Pol was constructed by transfecting an Ad-DNA Pol gene expression plasmid into 293 cells. 197 The cell line expressed the 140-kDa DNA polymerase protein and supported the replication and growth of H5ts36, an Ad with a ts mutation of the Ad polymerase protein. This cell line was further constructed with a pRSV-pTP expression plasmid and was developed into an Ad polymerase and pTP-expressing 293 cell line. 198 The application potential of these cell lines needs to be explored further.
E1-and E4-complementing cell line.
In an attempt to generate E1-, E3-, and E4-deleted Ad vectors with a gene delivery capacity of Յ11 kb, Ad E1-, E4-, and protein IX (pIX)-complementing cell lines were constructed based on stable transfection of 293 cells with plasmids containing the E4 transcription unit and pIX coding sequences under the control of an inducible mouse mammary tumor virus or metallothionin promoter, respectively. 199 Two cell lines, VK2-20 and VK10-9, that express both E4 and pIX proteins as well as E1, allowed the rescue and propagation of an Ad recombinant, Ad5 dlE3,4, containing a 2.7-kb E3 deletion and a 2.8-kb E4 deletion in addition to an insertion of plasmid DNA sequences in E1A. Another attempt involved stable transfection of the E4 open reading frame 6 expression plasmid into 293 cells to establish E1-E4 cell lines. 200 The new cell lines allowed isolation of more disabled Ad vectors that have both E1 and E4 deletions. It was shown that doubly deleted vectors blunted cellular immunity and prolonged transgene expression, which were significant improvements compared with the E1-deleted versions of the vectors.
Other Ad-helper cell lines. Other Ad-helper cell lines have been developed according to the need for the generation and propagation of new Ad vectors, such as the 293 cell line that expresses Cre recombinase. 201 Several new Ad-helper cell lines have also been made from 293 or A549 cells to express certain proteins such as the tetracycline repressor or a fusion protein, the tet-KRAB repressor protein, 202 for support of mini-Ad vector systems or for the specific control of transgene expression during viral amplification (D. Ayares et al, unpublished data).
Strategy and feasibility for development of mini-Ad vectors
The principle of increasing the gene delivery capacity and minimizing the toxicity and immunogenicity of Ad vectors is directed ultimately to produce a type of vector that is deleted of the entire coding sequence found in the wt Ad genome but retains the minimal cis element of the viral genome required for replication and packaging of the vector DNA (a so-called mini-Ad vector). The capacity of the mini-Ad vectors can be Յ36 kb. The viral proteins required for DNA replication and encapsidation of the mini-Ad vectors are provided in trans from a helper Ad (trans-complementation). To generate relatively pure preparations of the mini-Ad virions, packaging of the helper Ad genome should be controlled through a selective attenuation mechanism, whereas that of the mini-Ad vector genome should be allowed to proceed. In the absence of the mini-Ad vector genome, the helper Ad should be able to replicate alone in a controlled manner separately. In such a design, the Ad-helper cell line is necessary for the E1 complementation of the helper virus and may also provide other functions for packaging attenuation of the helper viral genome and enhancement of the mini-Ad vector replication. If the separation from the helper virus is not sufficient during the preparation of the mini-Ad vector, other biochemical or physical methods will be applied for further purification. A basic design of a mini-Ad vector system is diagrammed in Figure 4 .
The feasibility for successful development of the mini-Ad vector system is based on the following observations:
1. The origins of Ad DNA replication are localized in the ITR of the viral genome. 26 2. The DNA replication of Ad, which is uniquely primed by the covalently bound TP at each 5Ј end, 203 indicates an asymmetric replication of a unit-length linear molecule. 204 Thus, linear unit-length molecules are the substrates for packaging. 205 3. The packaging signal for viral encapsidation is localized between 194 -385 bp (0.5-1.1 mu) at the left end of the viral genome. 33 This signal mimics the protein recognition site in phage DNA, where a specific sequence close to the left end but outside the cohesive end sequence mediates the binding to proteins that are required to insert DNA into the head structure. 206 
Studies of E1-substituted vectors of Ad demonstrated
that a fragment of the left end of the viral genome as short as 450 bp (0 -1.25 mu) was enough to allow recombinant virus to be packaged in 293 cells. 207 In the cell line W162, 191 constitutive expression of E4 In the presence of the mini-Ad vector genome, the helper Ad also supports DNA replication of the mini-Ad vector genome, which is preferentially packaged because it contains a wt (unmodified) packaging signal that has a high affinity (relative to the modified signal of the helper virus) for the limiting amount of the packaging proteins. 35, 36 Purification of the mini-Ad vector can be achieved by biochemical or physical methods such as banding the virus on CsCl gradients using an ultracentrifuge.
proteins supported the propagation of E4 deletion (92) (93) (94) (95) (96) (97) (98) (99) The process of Ad genomic replication, transcription, and encapsidation is tightly controlled in a precise temporal manner. As long as the trans-complementation from the helper virus or from both the helper virus and the helper cell line to the mini-Ad vectors is well designed and not lacking critical elements, the viral propagation process should be possible. The success and level of evolution for the development a mini-Ad vector system are largely dependent upon the design and development of the helper Ad.
Development of Ad-helper viruses
The development of helper Ads for the support of packaging and propagation of rAds that have a large or total deletion of viral coding sequences has taken the course of either directly using wt Ad, adapting E1-deleted Ad as helper, designing and testing packaging signal-mutated Ad or constructing helper viruses that can be invoked to delete their packaging signal, and so on.
wt Ad as a helper. Early efforts were directed toward the rescue of large lethal-deletion rAd vectors using wt as a helper Ad. Generation, propagation, and partial purification of a helper virus-dependent Ad vector were reported. 212 This vector system was designed to replace an essential region of the viral genome (L1, L2, VAI, VAII, and pTP, a 7284-bp fragment between two SalI sites of Ad5 genome) with an indicator gene, Sr␣␤-geo (a bifunctional fusion gene of E. coli ␤-gal and the neomycin resistance gene). In the presence of wt Ad as a helper, the vector DNA was packaged and propagated as transducing viral particles at a titer of 4 ϫ 10 6 transducing particles per mL. The recombinant virus could be partially purified from the helper virus by CsCl equilibrium density-gradient centrifugation. The significance of this attempt is that it showed that a largeportion replacement of the essential genome from an Ad vector would still allow delivery of an indicator gene with the trans-complementation of a helper Ad. However, optimization of the recombinant vector structure and design of the helper Ad were not addressed.
E1-deleted Ad as a helper.
Another attempt along this line of approach was to use E1-substituted Ad as the helper and an Ad vector that had the entire Ad codingsequence replaced by a reporter gene expression cassette. In one of the studies, an E1-substituted Ad carrying the alkaline phosphatase (H5.CBALP) was used to support the propagation of a rAd deleted of all viral coding sequences (⌬rAd). 213 Another study used the E1-deleted Ad with the human placental alkaline phosphatase expression cassette as a helper Ad. 214 Both designs did not control the propagation or encapsidation of the helper virus along with that of the rAd. The contamination and dominant suppression of helper virus in the preparation of the rAd vectors were the crucial problems that remained to be solved.
Packaging-attenuated Ad as a helper.
To minimize the contamination of the helper Ad and generate high-titer mini-Ad, a controlled or conditionally attenuated helper Ad needs to be developed. Selective disabling of the packaging of the helper Ad became a logical solution. The technical approaches used to complete this strategy have primarily been reported in two aspects, a packaging signal partial deletion [215] [216] [217] and conditional deletion, 47, 218 although other designs to manipulate the packaging signal or packaging process of the helper virus can also be considered, such as a synthetic packaging signal, packaging blockage by specific DNA-binding, packaging signal relocation, etc.
A helper Ad with a partial deletion in the packaging signal was based on the studies of constructs in Hearing's laboratory (State University of New York, Stony Brook, NY). 34, 35 In these studies, manipulation (partial deletion or insertion) of the Ad packaging sequences resulted in a series of mutants that have different degrees of impaired packaging efficiency. So far, two groups have reported on the generation and characterization of the helper Ad with packaging signal mutations based on Hearing's constructs. [215] [216] [217] One helper (SV5) based on the dl309-267/358, 34 has a 91-bp deletion within the packaging signal and an E1A deletion (480 -1339 bp) with the rest of wt Ad5 genome. 215 The other helper Ad (AdH␤), based on dl309-194/243:274/358, 35 has packaging signal partial deletions (194 -243 and 274 -358 bp) and a complete E1 deletion (452-3328 bp). 216, 217 Both helper Ads can be propagated as single viruses in E1-complementing helper cells at a lower (ϳ100-fold less) efficiency than the E1-deleted-type viruses and have successfully supported the generation and propagation of mini-Ad vectors.
Another innovative development of packaging attenuation of the helper Ad was to apply the LoxP/Cre system to conditionally delete the Ad packaging signal. In this design the Ad packaging sequence plus a neomycin-resistant gene cassette (total of 1452 bp) were flanked by the LoxP sequences (or floxed); subsequently, they could be excised to form a packaging signal-deleted helper in an Ad-helper cell line that expresses Cre recombinase such as 293-Cre. 218 The helper virus DNA replicated at a normal level and consequently could express all of the functions necessary in trans for the replication and packaging of a mini-Ad vector genome containing the appropriate cis-acting elements. Serial passage of the vector in helper-Ad-infected 293-Cre cells resulted in a 10-fold increase in vector titer per passage. The vector could be further purified from the residual helper virus by CsCl banding. Contamination of the helper Ad to the mini-Ad vector was estimated to be Ͻ0.01% in a large-scale preparation of 10 10 transducing virions/mL. 218 A similar study took the same technical approach using the LoxP/Cre system to construct a negatively packaging-selected Ad known as ⌿5. 47 The ⌿5 virus has its packaging signal flanked by the LoxP sites. When ⌿5 was grown in cells making a high level of Cre recombinase, the packaging signal was deleted and the yield of ⌿5 was reduced to 5% of the wt level. The main problem that this study encountered was the instability of the ⌿5 virus. Homologous recombination between ⌿5 and the mini-Ad vector (called gutless virus) seemed to be one source of instability, which could be corrected partially by adding a LoxP site in the gutless virus before the packaging signal. Any recombination in the packaging sequence between the two viruses would then regenerate the initial molecules. The second source of instability was the deletion of one of the two LoxP sites from the ⌿5 viral genome, which allowed the ⌿5 viruses to escape packaging attenuation. Further improvement of the packaging-deleted helper Ad is needed.
Development of mini-Ad vectors
The principle of mini-Ad has been clearly demonstrated by the naturally existing hybrid viruses of Ad5-SV40 and Ad2-human genomic DNA, in which the entire coding sequences of Ad were replaced by heterologous DNA. 209, 210 The challenges for the successful development of mini-Ad vectors have to do with whether the packaging efficiency, stability, titer, infectivity, and reduced immunogenicity of the vector can be harnessed and optimized to meet the requirements of in vivo gene therapy.
General design of mini-Ad vectors.
The design of mini-Ad vectors has been focused primarily on how to maximally remove viral sequences from the Ad vector based on an understanding of the structure and function of both the ITR and packaging signal of the virus. The vectors thus produced have a minimal amount of viral cis-acting elements such as ITRs and packaging signals. The room created in the mini-Ad vector can be used to deliver transgenes, regulatory elements for the retention and expression of the transgene, and other stuffer sequences. The mini-Ad vectors reported thus far all have a similar structure. For example, one vector called ⌬rAd.CMVlacZ or ⌬rAd.CBCFTR contains a cis element of the Ad5 (left 1-360 bp and right 35,353 bp) to carry the reporter or therapeutic gene expression cassette. 213 Other vectors known as encapsidated Ad minichromosomes have the left end (0 -810 bp) and right end (994 bp) of Ad5 cis element flanking the dystrophin gene (for muscular dystrophy) and ␤-gal gene expression cassettes. 214 The mini-Ad vector AdDYS␤-gal is different from the two vectors described above, and uses the same left terminus of Ad5 (1-358 bp) to hold a nonviral recombinant genome containing both the dystrophin gene and the ␤-gal gene expression cassette. 215 Whether this design can enhance mini-Ad packaging needs to be further tested. Optimization of the design of mini-Ad backbone has not been well explored up to now. Because the total viral-coding genome is removed from the mini-Ad vector, the virus may be deficient in some function. The deficiency could be in any function requiring a cis-active component, such as replication, packaging, binding sites for the viral core proteins, directing the viral DNA to a proper location, stabilizing the DNA in a right topology, or playing a structural role of DNA in viral particles.
Optimal packaging size of mini-Ad vectors. The length of the mini-Ad vector genome was soon found to be critical for the packaging efficiency, which significantly affects the titer of mini-Ad vectors. It was found that the ⌬rAd.CMVlacZ vector had concatamerizations of the vector genomes through head-tail, head-head, and tailtail linkages. 213 In another study, a series of vectors with sizes ranging from 15.1 to 33.6 kb was constructed and tested to determine their relative packaging efficiency in the LoxP/Cre helper-dependent system. 219 It was shown that vectors with genomes that were Ն27.7 kb were packaged with equal efficiencies, whereas vectors with smaller genomes were inefficiently packaged. A 15.1-kb vector, approximately half the size of the wt Ad, was packaged with an efficiency that was in between that of the small (21.3-25.7 kb) and large (27.7-33.5 kb) vectors. Structural analysis found that the 15.1-kb vector was recovered primarily as a mix of head-to-tail and tail-totail covalent dimers, with a size of 30 kb. 219 However, a similar study on a series of mini-Ads with a progressive deletion of the Ad5 genome demonstrated a continual decrease of packaging efficiency from mini-Ad vectors with a genome size ranging from 32 kb to 6.5 kb. 216 These studies indicate that an optimal genome size (Ͼ75% of wt Ad genome) should be used for mini-Ad vectors to obtain high titers of the vectors.
Generation, propagation, and purification of mini-Ad vectors.
The methods used to generate mini-Ad vectors are similar to those used for E1-substituted Ad vectors. The majority of investigators used plasmid forms of mini-Ad genome with ITR fusion (minimal cis-element) to subclone transgene expression cassettes or other elements. The plasmids can be cotransfected with a helper Ad genome into helper cells or transfected and subsequently rescued by helper Ad infection. 213, 214, 216, 218 One approach used in vitro ligation of the Ad left end to the endless mini-Ad genome before cotransfection with the helper Ad genome into 293 cells. tion as opposed to the helper virus that is used in the LoxP/Cre helper system. The former can use regular E1 supplementary cell lines, whereas the latter needs to use the 293-Cre cell line at the final stage to suppress the packaging of the helper. 47, 218 Propagation of the mini-Ad was found to fluctuate with respect to that of the helper Ad. The ratio of the mini-Ad to the helper Ad was demonstrated to fluctuate around a 1:1 ratio, which was the optimal ratio for the production of both viruses. 216 The titers of the mini-Ad vectors varied with different vector/helper designs and propagation conditions. It was reported that the titer of the purified AdDYS␤-gal obtained was 1.4 ϫ 10 10 /mL, with a total of 4.9 ϫ 10 9 infectious particles generated from 1.6 ϫ 10 8 293 cells. 215 The lower density of the mini-Ad vectors allowed the separation of the vector from the helper Ad using CsCl banding techniques. 213, 214, 216, 218 Through two to three rounds of continuous CsCl gradient, the mini-Ad, which is usually located right above the helper Ad, could be purified (Ͼ99.99%) from the helper Ad. In one case, the mini-Ad vector did not form a sharp band, but instead spread in the gradient between the helper Ad and the incompletely formed virions. This resulted from the size heterogeneity of the concatamerization of the mini-Ad vector genome. 213 
Comparison of mini-Ad vectors with E1-substituted Ad vectors.
The mini-Ad vector has many virological and biochemical features close to those of E1-substituted Ad vectors. It was shown that the mini-AdGFP vector had an infectivity in vitro and in vivo that was similar to that of AdGFP in a direct comparison. 216 When the mini-Ad vector AdDYS␤-gal was injected intramuscularly into mdx mice, expression of dystrophin and ␤-gal from the vector increased with time and reached a peak at 28 days postinfection, with a gradual decrease in the proportion of muscle fibers expressing both genes by 42 days postinjection. 220 Further studies with AdDYS␤-gal in LacZ-transgenic mice resulted in a persistent expression of ␤-gal for Ն84 days, with no evidence of inflammation or significant loss of the vector DNA; 221 this is a great improvement over the expression pattern of E1-substituted Ad vectors using similar therapeutic approaches. 222, 223 A recent study by Kochanek et al. on mini-Ad vector carrying the genomic sequence of the full-length ␣1AT gene demonstrated a long-term (Ͼ13 weeks) expression of ␣1AT at 1 g/mL after i.v. administration of the vector (reported at the 1997 Keystone Gene Therapy Symposium). Longer-term gene expression of mini-AdGFP or mini-AdhFVIII vectors (that contained a cassette of full-length human factor VIII cDNA flanked by the albumin promoter and an albumin gene fragment) was also observed in immune-competent mice in comparison with the AdE1 vector versions. 216 Whether mini-Ad vectors have reduced immunogenicity and cytotoxicity in comparison with E1-substituted Ad vectors needs to be evaluated.
To date, the mini-Ad vector has been developed mainly with the intention of minimizing the immunogenicity and increasing the gene-carrying capacity of Ad vectors. The potential of the system for designing novel vectors specifically for gene therapy of cancer is great, particularly for the simultaneous delivery of multiple genes that are useful for destroying cancer cells and inducing anticancer immune responses.
Other considerations
Basically, new vector development has been focused on how to increase the delivery capacity and minimize or control the immunogenicity and cytotoxicity of Ad vectors. In addition to research and the development of mini-Ad vectors, other strategies have also been considered to artificially engineer Ad vectors, as discussed below. In addition, surface modification and protein engineering of Ad vectors to render the vector with targeting capability or to enhance the infectivity of the vector have also been completed.
Surface modification and targeting.
To develop a targeted Ad vector, it is necessary both to ablate endogenous viral tropism and to introduce novel tropism. Modification of the penton fibers for Ad vector targeting is a rational approach. The Ad5 fiber protein is a long trimeric protein that protrudes from the virion surface. The distal end of the fiber contains a knob-like C terminus that interacts with the CAR. 15 Modification of the fiber, therefore, can alter the native tropism to overcome cellular limitation due to lack of the CAR for Ad infection. To this end, surface-modified Ad vectors were made by addition of a short peptide ligand to the fiber protein 224 or by incorporation of a heparin-binding domain (8-amino acid polylysine) into the knob of the fiber protein. 225 The new vectors increased the gene transfer efficiency to target cells from 10-to 300-fold. Another method based on homologous recombination between two plasmids was developed to generate novel Ad vectors with variant fibers or chimeric fibers composed of the tail and shaft domain of Ad5 and the knob domain of Ad3. 226 This modification was shown to alter the receptor recognition profile of the virus containing the fiber chimera.
Neutralizing antifiber Ab or engineered Ab complex is another approach that has been applied to specifically engage viral particles to target cells. 225, 227 In one design, the folate receptor, which is overexpressed on the surface of a variety of malignant cells, was chosen as a target and the ligand, folate, was conjugated to the neutralizing Fab fragment of an antifiber monoclonal. 227 A complex of folate-Fab-Ad vector carrying the luciferase reporter gene was shown to redirect Ad infection of target cells via the folate receptor at a high efficiency. In another attempt, a bispecific Ab (bsAb) that comprised a monoclonal Ab to the FLAG peptide epitope, DYKDDDDK, and a monoclonal Ab to ␣ v integrins was constructed to target ␣ v integrins that are abundantly expressed on endothelial or smooth muscle cells. 228 In conjunction with the bsAb, a new vector, AdFLAG was generated. Complexing AdFLAG with the bsAb increased the ␤-glucuronidase transduction of human venule endothelial cells and human intestinal smooth muscle cells by 7-to 9-fold compared with transduction by AdFLAG alone. The increased transduction efficiency was shown to occur through the specific interaction of the complex with ␣ v integrins.
The bsAb approach was also applied to T-cell transduction. 229 T cells are primary targets in numerous gene therapy protocols. However, the use of subgroup C Ad2 or Ad5 as a vector to transduce T cells is limited by its poor transduction efficiency for these cells. In a recent study, this hurdle was overcome using the bsAb with specificities for human CD3 and for the FLAG epitope to redirect the virus to human T cells. The anti-FLAG plus anti-CD3 bsAb increased AdFLAG binding by 30-fold, induced the efficient uptake of AdFLAG into the target cells, and led to a 100-to 500-fold increase in the transduction of resting T cells. Moreover, fluorescence-activated cell sorter analysis showed that 25-90% of the T cells were transduced by the bsAb-complexed AdFLAG at an MOI of between 20 and 100 active particles per cell. 229 The modifications of Ad vectors on the surface have demonstrated that Ad vectors can be genetically engineered to target certain types of cells, including cells that are originally not sensitive to Ad infection due to a lack of the receptors to Ad. Further development along this line would render Ad vectors with a wider spectrum of application in gene therapy for cancer.
Artificial Ad vectors.
Efforts to reduce the immunogenic components in the capsid proteins as well as viral DNA in vector backbone have driven the development of artificial Ad vectors such as Ad dodecahedron, a new vector for human gene transfer. 230 Ad penton is a complex of two oligomeric proteins, a penton base and fiber, that is involved in cell attachment, internalization, and liberation of viral DNA into the cytoplasm. 18, 22 The dodecahedron was made of the Ad pentons or penton bases, which are packed as in the Ad virion, on the 12 5-fold vertices of an icosahedron; 231 the diameter (distance between tips of opposite fiber heads) was almost half that of the Ad virion (49 Ϯ 0.7 nm). Because the internal cavity of dodecahedron is too small to accommodate any DNA of Ͼ100 bp, a bifunctional peptide composed of 20 amino acids corresponding to the N terminus of Ad3 fiber with a C-terminal extension of 20 lysines was designed to condense and link the plasmid DNA for gene transfer to dodecahedron particles. The dodecahedron retained many of the advantages of Ad for gene transfer, such as efficiency of entry, efficient release of DNA from endosomes, and a wide range of cell and tissue targets. Because it consists of only one or two Ad proteins instead of the 11 contained in an Ad virion and does not contain the viral genome, it is potentially a safer alternative to rAd vectors, although the immunogenicity of the dodecahedron vector in vivo needs to be assessed. The potential hurdles of scale-up production and the stability of the vector complex may also need to be addressed.
PROSPECTS OF Ad VECTORS
Development and application potential of Ad vectors rAds, their helper cell lines, and related technologies, as discussed above, have been developed and applied for many aspects of usage through a course of virological research, molecular and cellular biology studies, recombinant protein expression, recombinant vaccine, and gene therapy. These technologies have demonstrated the great application value of this virus. The potential for further development of this vector system is still high.
Construction of novel vectors for gene therapy
The mini-Ad vector represents a new developmental direction of Ad vectors. Owing to the entire viral genome deletion, how to properly and effectively use the created DNA-delivery capacity is one of the important areas for the optimization of this vector system. There are many possibilities to be explored. For example, mini-Ad vectors can be equipped with certain elements or mechanisms for transgene retention and operation in target cells.
The application of segments of human genomic DNA that provide efficient replication initiation and sequences derived from Epstein-Barr virus (oriP and Epstein-Barr nuclear Ag-1, EBNA) that provide nuclear retention for constructing episomal vectors of gene transfer has demonstrated greatly prolonged gene expression, with vector DNA detectable at 2 months post-transfection. 232 This offers an alternative design for maintaining the mini-Ad genome in the target cell.
A site-specific integration mechanism such as the adeno-associated virus ITR/Rep integration system may also be applicable in the creation of the integratable transgene expression cassettes delivered by mini-Ad. The proof-of-concept experiments have been completed successfully. 233 The principle of chimeric or hybrid Ad vectors, which occur naturally in Ad-SV40 hybridization, 209,234 -237 can be further applied to Ads to combine or accommodate other viral genetic components or functions such as retroviral elements. An Ad/retroviral chimeric vector system was reported recently. 238 In this design, Ad vectors induced target cells to function as transient retroviral producer cells in vivo. The progeny retroviral vector particles were shown to achieve a stable transduction of neighboring cells. 239 This represents an alternative strategy to render Ad vectors functionally integrative for long-term gene delivery.
Anti-cancer complementary-Ad vectors
Further development of the methodology along the line of Ad-mediated gene therapy of cancer is to combine the tumor-specific replicative Ad vector with immunomodulating gene therapy of cancer over and beyond the wt Ad-based, E1A promoter-substituted Ad vectors that have limited capacity to carry other transgenes. In addition, to carry multiple-expression cassettes of immunomodulating genes, it would be necessary to delete certain sequences from the Ad viral genome to make space for them. With this consideration, the mini-Ad vector system can be applied. Complementation between mini-Ads and helper Ads can be designed to form a tumor-specific replicative dual-Ad vector system. Proof of concept for such an anticancer complementary-Ad system has been implicated by experiments in which the activation of replication of an E1-deleted Ad vector was accomplished by trans-complementation using an E1A-plasmid. 240 Such systems would depend upon the propagation of two complementing components that are regulated for their propagation in tumor cells similar to tumor-specific RCA vectors. 145, 146 Future perspectives The continued development of Ad vectors may progress further by exploiting the virological and biological traits of Ads, such as their high infectivity, vigorously replicative capability, relative stability, and safety. The research, development, and application of Ads that have been systematically carried out and well documented thus far have laid down a solid base for the construction of many different useful vector systems. Future directions for the development of Ad vectors may still be along the following two lines: gene therapy of cancer and gene therapy of hereditary diseases. Limitations or weaknesses such as the immunogenicity of the vector system will still impose hurdles in the progress of developmental activities. However, such hurdles can generally be circumvented as progress is made in the related areas of science and technology. Optimization or innovation of either the whole system or of certain specific vector designs will evolve along with overcoming these hurdles.
